AU2006251138C1 - Tricyclic spiro derivatives as CRTH2 modulators - Google Patents

Tricyclic spiro derivatives as CRTH2 modulators Download PDF

Info

Publication number
AU2006251138C1
AU2006251138C1 AU2006251138A AU2006251138A AU2006251138C1 AU 2006251138 C1 AU2006251138 C1 AU 2006251138C1 AU 2006251138 A AU2006251138 A AU 2006251138A AU 2006251138 A AU2006251138 A AU 2006251138A AU 2006251138 C1 AU2006251138 C1 AU 2006251138C1
Authority
AU
Australia
Prior art keywords
chloro
indole
pyrrolidin
trioxospiro
acetic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006251138A
Other languages
English (en)
Other versions
AU2006251138A1 (en
AU2006251138B2 (en
Inventor
John Frederick Atherall
Dennis Church
Christophe Cleva
Stefano Crosignani
Jacqueline A. Macritchie
Cedric Merlot
Patrick Page
Doris Pupowicz
Matthias Schwarz
Eric Sebille
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Merck Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono SA filed Critical Merck Serono SA
Publication of AU2006251138A1 publication Critical patent/AU2006251138A1/en
Assigned to MERCK SERONO SA reassignment MERCK SERONO SA Alteration of Name(s) of Applicant(s) under S113 Assignors: LABORATOIRES SERONO S.A.
Application granted granted Critical
Publication of AU2006251138B2 publication Critical patent/AU2006251138B2/en
Publication of AU2006251138C1 publication Critical patent/AU2006251138C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2006251138A 2005-05-24 2006-05-23 Tricyclic spiro derivatives as CRTH2 modulators Ceased AU2006251138C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05104428.7 2005-05-24
EP05104428 2005-05-24
US68863105P 2005-06-08 2005-06-08
US60/688,631 2005-06-08
PCT/EP2006/062545 WO2006125784A1 (en) 2005-05-24 2006-05-23 Tricyclic spiro derivatives as crth2 modulators

Publications (3)

Publication Number Publication Date
AU2006251138A1 AU2006251138A1 (en) 2006-11-30
AU2006251138B2 AU2006251138B2 (en) 2012-08-09
AU2006251138C1 true AU2006251138C1 (en) 2013-08-29

Family

ID=35478408

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006251138A Ceased AU2006251138C1 (en) 2005-05-24 2006-05-23 Tricyclic spiro derivatives as CRTH2 modulators

Country Status (20)

Country Link
US (1) US8236963B2 (https=)
EP (1) EP1891075B1 (https=)
JP (1) JP5567268B2 (https=)
KR (1) KR101333861B1 (https=)
CN (1) CN101300259B (https=)
AR (1) AR055959A1 (https=)
AT (1) ATE529429T1 (https=)
AU (1) AU2006251138C1 (https=)
BR (1) BRPI0610209A2 (https=)
CA (1) CA2602965C (https=)
DK (1) DK1891075T3 (https=)
ES (1) ES2375614T3 (https=)
MX (1) MX2007014256A (https=)
NZ (1) NZ562772A (https=)
PL (1) PL1891075T3 (https=)
PT (1) PT1891075E (https=)
RU (1) RU2478639C2 (https=)
UA (1) UA90145C2 (https=)
WO (1) WO2006125784A1 (https=)
ZA (1) ZA200709819B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0715179A2 (pt) 2006-08-07 2013-06-11 Actelion Pharmaceuticals Ltd composto, composiÇço farmacÊutica e uso de um composto
US20120115895A1 (en) 2009-07-15 2012-05-10 Merck Serono S.A. Tricyclic indole-derived spiro derivatives as crth2 modulators
KR20120099462A (ko) 2009-11-12 2012-09-10 더 리젠츠 오브 더 유니버시티 오브 미시건 스피로-옥신돌 mdm2 길항제
PT2558447E (pt) 2010-03-22 2014-11-25 Actelion Pharmaceuticals Ltd Derivados de 3-(heteroarilamino)-1,2,3,4-tetrahidro-9hcarbazol e o seu uso como moduladores do receptor de prostaglandina d2
AU2011326395B2 (en) 2010-11-12 2016-01-07 Ascenta Licensing Corporation Spiro-oxindole MDM2 antagonists
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
DK2697223T3 (en) 2011-04-14 2016-09-05 Actelion Pharmaceuticals Ltd 7- (heteroaryl-amino) -6,7,8,9-tetrahydro-pyrido [1,2-a] indole-acetic acid derivatives and their use as prostaglandin D2 receptor
US8629141B2 (en) 2011-05-11 2014-01-14 The Regents Of The University Of Michigan Spiro-oxindole MDM2 antagonists
EP2790696A1 (en) 2011-12-16 2014-10-22 Atopix Therapeutics Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
CN103554118B (zh) * 2013-10-15 2015-08-19 华东师范大学 四氢呋喃并苯并二氢吡喃多环化合物及其应用
CN103554119B (zh) * 2013-10-15 2015-09-16 华东师范大学 四氢呋喃并苯并二氢吡喃多环化合物的制备方法
CN103554120B (zh) * 2013-10-16 2015-06-24 华东师范大学 3,3-螺(2-四氢呋喃)氧化吲哚多环状化合物的制备方法
CN103554121B (zh) * 2013-10-16 2015-06-24 华东师范大学 3,3-螺(2-四氢呋喃)氧化吲哚多环状化合物及其应用
AR099767A1 (es) 2014-03-17 2016-08-17 Actelion Pharmaceuticals Ltd Derivados del ácido acético azaindol y su uso como moduladores del receptor de prostaglandina d2
KR20160133536A (ko) 2014-03-18 2016-11-22 액테리온 파마슈티칼 리미티드 아자인돌 아세트산 유도체 및 프로스타글란딘 d2 수용체 조절제로서의 이의 용도
US9745253B2 (en) 2015-03-13 2017-08-29 Forma Therapeutics, Inc. Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
ES2733468T3 (es) 2015-07-15 2019-11-29 Hoffmann La Roche Derivados de etinilo como moduladores de los receptores metabotrópicos de glutamato
AU2016323262B2 (en) 2015-09-15 2020-11-19 Idorsia Pharmaceuticals Ltd Crystalline forms
RU2631856C1 (ru) * 2016-05-04 2017-09-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Чувашский государственный университет имени И.Н. Ульянова" Способ получения аммонийных солей 3-амино-8-гидрокси-1,6-диоксо-4-циано-2,7-диазаспиро[4.4]нон-3-ен-2-идов
WO2018015235A1 (en) 2016-07-18 2018-01-25 F. Hoffmann-La Roche Ag Ethynyl derivatives
CN109384787B (zh) * 2017-08-08 2021-04-16 沈阳药科大学 一种一价银催化的氢化吡啶螺二氢吲哚环的合成方法
CN109384794B (zh) * 2017-08-08 2020-06-19 沈阳药科大学 质子酸催化的一类四环吲哚骨架的合成方法
CN109369658B (zh) * 2017-08-08 2020-01-31 沈阳药科大学 一种螺[吡咯烷-3,3`-氧化吲哚]环系的合成方法
KR101857408B1 (ko) 2018-02-28 2018-05-14 경북대학교 산학협력단 탈모 예방 또는 치료용 조성물
EP3902805A4 (en) 2018-12-28 2023-03-01 SPV Therapeutics Inc. CYCLINE-DEPENDENT KINASE INHIBITORS
CN112876488B (zh) * 2021-02-18 2021-12-21 苏州大学 螺环吲哚啉衍生物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2388540A (en) * 2002-05-17 2003-11-19 Bayer Ag New use of Ramatroban

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52879B1 (en) * 1981-05-12 1988-03-30 Ici Plc Pharmaceutical spiro-hydantoin derivatives
IE53102B1 (en) 1981-05-12 1988-06-22 Ici Plc Pharmaceutical spiro-succinimide derivatives
US5948807A (en) * 1997-09-03 1999-09-07 Regents Of The University Of Minnesota Spiroindanamines and Spiroindanimides
NZ528846A (en) * 1999-03-12 2005-05-27 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
SE0200411D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
AU2003277285B2 (en) 2002-10-04 2007-12-13 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
EP1556356B1 (en) 2002-10-21 2006-05-31 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as crth2 antagonists
DE60303238T2 (de) 2003-04-25 2006-09-14 Actimis Pharmaceuticals, Inc., La Jolla Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
US20050038070A1 (en) 2003-07-09 2005-02-17 Amgen Inc. Asthma and allergic inflammation modulators
MXPA06011891A (es) 2004-04-20 2007-04-24 Pfizer Metodo para tratar el dolor neuropatico.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2388540A (en) * 2002-05-17 2003-11-19 Bayer Ag New use of Ramatroban

Also Published As

Publication number Publication date
EP1891075A1 (en) 2008-02-27
ES2375614T3 (es) 2012-03-02
JP2008542238A (ja) 2008-11-27
JP5567268B2 (ja) 2014-08-06
RU2007147430A (ru) 2009-06-27
CN101300259B (zh) 2013-08-28
AU2006251138A1 (en) 2006-11-30
ATE529429T1 (de) 2011-11-15
NZ562772A (en) 2010-01-29
UA90145C2 (ru) 2010-04-12
AR055959A1 (es) 2007-09-12
RU2478639C2 (ru) 2013-04-10
CA2602965C (en) 2013-12-31
US8236963B2 (en) 2012-08-07
BRPI0610209A2 (pt) 2010-06-01
US20090318486A1 (en) 2009-12-24
PL1891075T3 (pl) 2011-12-30
KR101333861B1 (ko) 2013-11-28
PT1891075E (pt) 2011-11-10
ZA200709819B (en) 2009-09-30
MX2007014256A (es) 2008-03-26
DK1891075T3 (da) 2011-12-19
CN101300259A (zh) 2008-11-05
CA2602965A1 (en) 2006-11-30
EP1891075B1 (en) 2011-10-19
KR20080031191A (ko) 2008-04-08
AU2006251138B2 (en) 2012-08-09
WO2006125784A1 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
AU2006251138C1 (en) Tricyclic spiro derivatives as CRTH2 modulators
US11337970B2 (en) Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
RU2695664C1 (ru) Производные имидазопиридина в качестве модуляторов активности tnf
HRP20000153A2 (en) Carboxamidothiazole derivatives, preparation, pharmaceutical compositions containing them
KR20110106450A (ko) 바이시클릭 피라졸로-헤테로사이클
CA2724294A1 (en) Glucagon receptor antagonists, compositions, and methods for their use
JP2015147792A (ja) β−セクレターゼ阻害剤
AU2008265655A1 (en) Substituted imidazoheterocycles
KR20060006057A (ko) 카나비노이드 수용체 리간드 및 그의 용도
CN101621931A (zh) 杂芳基酰胺衍生物
TW202019408A (zh) 稠合三環雜環化合物及其治療用途
AU2018357878A1 (en) Spirocyclic compounds as farnesoid X receptor modulators
US8835422B2 (en) Substituted imidazoheterocycle derivatives
EP4612146A1 (en) Ahr agonists
US20120077816A1 (en) Substituted heterocycles and their use as allosteric modulators of nicotinic and gabaa receptors
HK1121146A1 (en) Tricyclic spiro derivatives as crth2 modulators
HK1121146B (en) Tricyclic spiro derivatives as crth2 modulators
JP2026503850A (ja) Trpa1阻害剤としての二環式イミド化合物
AU2011236110B2 (en) Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 19 MAR 2013 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 19 MAR 2013

MK14 Patent ceased section 143(a) (annual fees not paid) or expired